vegf-a

Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ monoclonal antibody that binds mouse VEGF-A with high affinity, functioning as a potent VEGF-A inhibitor. Anti-Mouse VEGF-A Antibody demonstrates significant antitumor activity in gastric cancer xenograft models, supporting its relevance in angiogenesis blockade studies, tumor microenvironment research, and preclinical evaluation of VEGF-targeted therapies.

Vanucizumab is a bispecific humanised monoclonal antibody that simultaneously inhibits the receptor interactions of VEGF-A and Angiopoietin-2 (Ang-2), exhibiting anti-angiogenic and anti-cancer effects, and can be used for the treatment of advanced solid tumours.

Anti-VEGF165/VEGFA Antibody (4A225) is a Rabbit IgG monoclonal antibody targeting Human, Cynomolgus VEGF165/VEGFA.

Anti-VEGF165/VEGFA Antibody (5L924) is a Rabbit IgG monoclonal antibody targeting Human, Cynomolgus VEGF165/VEGFA.

Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.

Anti-VEGF Antibody is a neutralizing monoclonal antibody targeting vascular endothelial growth factor (VEGF). It inhibits endothelial cell proliferation and neo-angiogenesis by binding to free VEGF and preventing receptor interaction, widely used in research on solid tumors and vasoproliferative eye diseases.

Anti-Human/Rat VEGF Antibody（A.4.6.1） is a monoclonal antibody targeting human and rat VEGF and can be used in angiogenesis research.

Anti-Mouse VEGF Antibody（G6-31） is a monoclonal antibody targeting mouse VEGF and can be used in angiogenesis research.

Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes.

Sozinibercept (OPT 302; VGX-300) is a soluble form of Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) that potently inhibits the activity of Vascular Endothelial Growth Factor-C and -D (VEGF-C/D), key proangiogenic factors involved in promoting angiogenesis and vascular leakage. Additionally, Sozinibercept has been shown to inhibit diabetic retinal edema in rats [1] [2] [3].

Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interaction between EGFL7 and endothelial cells, and has an inhibitory effect on endothelial growth factor (VEGF).Parsatuzumab has been used in combination with other compounds for a long time. Combined use to study rectal cancer

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3].

Abicipar pegol (AGN-150998, MP0112), an anti-VEGF DARPin molecule, is a novel class of small ankyrin repeat domain-containing proteins designed for high specificity and affinity targeting. This compound effectively inhibits angiogenesis and vascular permeability, and has been applied in ocular inflammation-related disease studies through intravitreal injections, significantly reducing mean retinal thickness and leakage area [1] [2].

Vulinacimab (REGN910, SAR153192) is a humanized monoclonal antibody targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). By binding with high affinity to VEGFR2, it blocks the interaction of various ligands, including VEGF-A, with the receptor, thereby inhibiting downstream pro-angiogenic and pro-survival signaling pathways. It is a key tool for studying tumor angiogenesis and VEGFR2-related pathologies.

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC).

Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling.

Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.

Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Conbercept (KH902) is a fusion protein comprising the second immunoglobulin C-like domain of FLT1 and the third and fourth immunoglobulin C-like domains of KDR, linked to the Fc fragment of IGHG1. This monoclonal antibody targets VEGF receptors and is designed for therapeutic use. Conbercept [1].

DX-2240 is a human monoclonal antibody (mAb) that targets TIE1. It can inhibit tumor growth and render the tumor vasculature sensitive to anti-angiogenic agents (VEGF pathway inhibitors).

VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A, employed in cancer research.

AG01 is a monoclonal antibody targeting the anti-granular protein precursor (GP88). It inhibits the proliferation and migration of triple-negative breast cancer (TNBC) cells, reducing the expression of phosphorylated protein kinases such as p-Src, p-AKT, and p-ERK, as well as oncogenic proteins like Axl, c-MET, HIF-1α, and VEGF. In TNBC xenograft mouse models, AG01 suppresses tumor growth and the expression of Ki67 in vivo. AG01 is useful for research involving cancers like TNBC.

SSGJ-707 is a bispecific recombinant humanized IgG4 monoclonal antibody inhibitor that targets PD-1 and VEGF. It is applicable in cancer research, particularly for advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer.

Alacizumab is a human monoclonal antibody targeting KDR (VEGFR2). Alacizumab can be used for angiogenesis and oncology research, particularly studies involving VEGF/VEGFR signaling pathways.